NEW YORK (GenomeWeb News) – Cancer Genetics again lowered the amount it expects to raise in its pending initial public offering.

In a Form S-1/A filed with the US Securities and Exchange Commission on Monday, the Rutherford, NJ-based firm said that it expects to offer 1.85 million shares of stock in its IPO at a price of between $10 and $12 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.